Pradžia › Insulino rezistencija › Merilendas
Insulino rezistencija klinikiniai tyrimai Merilendas
7 tyrimai dėl Insulino rezistencija ieško dalyvių vietose Merilendas.
Miestai Merilendas
Oficialus tyrimo tekstas (anglų kalba)
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
- National Institute of Aging, Clinical Research Unit, Baltimore
Renkami dalyviai
Amžius nuo 55 iki 100 · Visoms lytims · Atnaujinta 2026-10-02 · NCT06274749Tirzepatide for Treatment of CCCA
- Johns Hopkins Outpatient Center, Baltimore
- Medical Pavilion at Howard County, Columbia
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-09-23 · NCT07734870Taste Bud-Derived Stem Cells in Humans
- National Institute of Aging, Clinical Research Unit, Baltimore
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-09-16 · NCT03366168Risk-informed Shared-decision Making Engagement Strategy for Patients With Prediabetes
- Johns Hopkins Community Physicians Frederick, Frederick
Renkami dalyviai
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-08-28 · NCT07553325Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
- Baltimore VA Medical Center Univ of Maryland, Baltimore
Renkami dalyviai
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-08-28 · NCT07599982Genetic Studies of Insulin and Diabetes
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
6 Months – 120 Years · Visoms lytims · Atnaujinta 2026-08-24 · NCT00001987Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
- National Institutes of Health Clinical Center, Bethesda
Renkami dalyviai2 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-08-18 · NCT05470504Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.